Mainz Biomed Announces Exercise of Over-Allotment Option
November 08 2021 - 1:45PM
Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),
a molecular genetics diagnostic company specializing in the early
detection of cancer, today announced the underwriters have
exercised their over-allotment option resulting in the issuance of
an additional 300,000 shares.
Mainz Biomed had previously announced the pricing of its $10
Million public offering of 2,000,000 shares on November 4th, 2021
at $5.00 per share. With the exercise and closing of the
underwriters' over-allotment option, the total gross proceeds to
the Company are $11.5 Million.
The Company commenced trading on the Nasdaq Capital Market on
November 5th, 2021.
Boustead Securities, LLC acted as sole underwriter for the
Offering.
The securities described above were sold by Mainz Biomed
pursuant to a registration statement, as amended, filed by the
Company with the Securities and Exchange Commission (the SEC),
which was declared effective on November 4th, 2021. The Offering
was made only by means of a prospectus. A copy of the final
prospectus related to the Offering may be obtained from Boustead
Securities, LLC, via email: offerings@boustead1828.com or by
calling +1 (949) 502-4408 or standard mail at Boustead Securities,
LLC, Attn: Equity Capital Markets, 6 Venture, Suite 395, Irvine, CA
92618, USA. In addition, a copy of the final prospectus relating to
the Offering may be obtained via the SEC's website at
www.sec.gov.
About Mainz Biomed N.V.
Mainz Biomed develops market-ready molecular genetic diagnostic
solutions for life-threatening conditions. The Company's flagship
product is ColoAlert, an accurate, non-invasive, and easy-to-use
early detection diagnostic test for colorectal cancer. ColoAlert is
currently marketed across Europe with FDA clinical study and
submission process intended to be launched in the first half of
2022 for U.S. regulatory approval. Mainz Biomed’s product candidate
portfolio includes PancAlert, an early-stage pancreatic cancer
screening test based on Real-Time Polymerase Chain Reaction-based
(PCR) multiplex detection of molecular-genetic biomarkers in stool
samples, and the GenoStick technology, a platform being developed
to detect pathogens on a molecular genetic basis.
For more information please visit
www.mainzbiomed.com
For media enquiries, please contact
press@mainzbiomed.com
For investor enquiries, please contact
ir@mainzbiomed.com
For underwriter enquiries, please contact
dan@boustead1828.com
Forward-Looking Statements
Certain statements made in this press release are
“forward-looking statements” within the meaning of the “safe
harbor” provisions of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements may be identified by the use of
words such as “anticipate”, “believe”, “expect”, “estimate”,
“plan”, “outlook”, and “project” and other similar expressions that
predict or indicate future events or trends or that are not
statements of historical matters. These forward-looking statements
reflect the current analysis of existing information and are
subject to various risks and uncertainties. As a result, caution
must be exercised in relying on forward-looking statements. Due to
known and unknown risks, actual results may differ materially from
the Company’s expectations or projections. The following factors,
among others, could cause actual results to differ materially from
those described in these forward-looking statements: (i) the
failure to meet projected development and related targets; (ii)
changes in applicable laws or regulations; (iii) the effect of the
COVID-19 pandemic on the Company and its current or intended
markets; and (iv) other risks and uncertainties described herein,
as well as those risks and uncertainties discussed from time to
time in other reports and other public filings with the Securities
and Exchange Commission (the “SEC”) by the Company. Additional
information concerning these and other factors that may impact the
Company’s expectations and projections can be found in its initial
filings with the SEC, including its Prospectus filed on October 12,
2021 and amended on October 25, 2021 and November 1, 2021. The
Company’s SEC filings are available publicly on the SEC's website
at www.sec.gov. Any forward-looking statement made by us in this
press release is based only on information currently available to
Mainz Biomed and speaks only as of the date on which it is made.
Mainz Biomed undertakes no obligation to publicly update any
forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise, except as required by law.
Mainz BioMed NV (NASDAQ:MYNZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mainz BioMed NV (NASDAQ:MYNZ)
Historical Stock Chart
From Apr 2023 to Apr 2024